Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00963-w
Abstract: Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in… read more here.
Keywords: induced ild; treatment; study; osimertinib induced ... See more keywords
OSIMERTINIB PNEUMONITIS MASQUERADING AS COVID-19 PNEUMONIA
Sign Up to like & getrecommendations! Published in 2021 at "Chest"
DOI: 10.1016/j.chest.2021.07.681
Abstract: TOPIC: Critical Care TYPE: Medical Student/Resident Case Reports INTRODUCTION: Osimertinib induced lung disease may present as a COVID pneumonia. We herein present a case of a 71 year old patient with hypoxic respiratory failure initially… read more here.
Keywords: covid pneumonia; case; patient; osimertinib induced ... See more keywords
Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
Sign Up to like & getrecommendations! Published in 2021 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2021.101450
Abstract: Herein, we report the case of an 84-year-old woman with epidermal growth factor receptor (EGFR) mutation exon 19 deletion postoperative recurrent lung adenocarcinoma. Osimertinib was administered as a first-line treatment; however, she was urgently admitted… read more here.
Keywords: treatment; disease; case; osimertinib induced ... See more keywords
Applied electric fields suppress osimertinib-induced cytotoxicity via inhibiting FOXO3a nuclear translocation through AKT activation.
Sign Up to like & getrecommendations! Published in 2019 at "Carcinogenesis"
DOI: 10.1093/carcin/bgz150
Abstract: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor against T790M-mutant non-small cell lung cancer (NSCLC). Acquired resistance to osimertinib is a growing clinical challenge that is not fully understood. Endogenous electric fields… read more here.
Keywords: akt; electric fields; osimertinib induced; activation ... See more keywords
1143: HYPOXIC RESPIRATORY FAILURE CAUSED BY OSIMERTINIB-INDUCED ACUTE FIBRINOUS AND ORGANIZING PNEUMONIA
Sign Up to like & getrecommendations! Published in 2021 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000810896.08898.49
Abstract: INTRODUCTION: Osimertinib is a molecular targeted antineoplastic tyrosine kinase inhibitor that is primarily used in the treatment of non-small cell lung cancer (NSCLC). It has been associated with the development of interstitial lung disease/pneumonitis that… read more here.
Keywords: fibrinous organizing; lung; acute fibrinous; day ... See more keywords
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211018028
Abstract: Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. Drug-induced pneumonitis is known to occur with osimertinib.… read more here.
Keywords: induced pneumonitis; steroid protection; osimertinib induced; osimertinib ... See more keywords
Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Internal Medicine"
DOI: 10.2169/internalmedicine.5435-20
Abstract: Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein… read more here.
Keywords: egfr; treatment; afatinib osimertinib; osimertinib induced ... See more keywords